Back to Authors

Viswanatha, David S.

Mayo Clinic

Mayo Clinic in Arizona

Citations 1

Concomitant Clonal CBFB::MYH11 and PDGFRB Fusions in a Case of De Novo Acute Myeloid Leukemia
Ding, Qiliang , Lewis, Natasha , Artymiuk, Cody J. , Olson, Renee M., He, Rong, Viswanatha, David S., Greipp, Patricia T. , Mendoza, Cinthya Zepeda, Lewis, Natasha E , Greipp, Patricia T , Zepeda-Mendoza, Cinthya J , He, Rong , Ketterling, Rhett P. , Viswanatha, David S., Zepeda‐Mendoza, Cinthya

Hematology Reports | March 23, 2026 | Volume: 18 | Issue: 2 | Pages: 24

10.3390/hematolrep18020024 Get It

Background: Acute myeloid leukemia (AML) with CBFB::MYH11 fusion and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) are genetically defined and typically mutually exclusive entities. Case Presentation: We report a unique case of de novo AML harboring two clonal, transcriptionally active class-defining fusions: CBFB::MYH11 and GOLGA4::PDGFRB. A 61-year-old woman presented with leukocytosis with neutrophilia, eosinophilia, and monocytosis; circulating blasts; and a markedly hypercellular marrow. Cytogenetic analysis revealed inv(16)(p13.1q22) and t(3;5)(p21;q32) in all 20 metaphases, and RNA sequencing confirmed expression of both CBFB::MYH11 and GOLGA4::PDGFRB fusions. In addition, an oncogenic WT1 frameshift variant was identified. Hematopathologic findings were largely consistent with AML with CBFB::MYH11 fusion but exhibited features reminiscent of PDGFRB-rearranged MLN-TK. The patient achieved complete remission following the standard 7 + 3 induction chemotherapy regimen for AML with gemtuzumab ozogamicin. Conclusions: This case illustrates the diagnostic challenges posed by concomitant class-defining alterations in hematologic neoplasms and underscores the importance of integrated genomic assessment.